, Volume 67, Issue 4, pp 169-173

Effect of recombinant human erythropoietin after allogeneic bone marrow transplantation

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.